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Trisomy 21DS is the most frequent genetic cause of intellectual disability characterized by the anomalous presence
of three copies of chromosome 21. One of the peculiar features of DS is the onset of Alzheimer's disease
neuropathology after the age of 40 years characterized by deposition of senile plaques and neuroﬁbrillary
tangles. Growing studies demonstrated that increased oxidative damage, accumulation of unfolded/damaged
protein aggregates and dysfunction of intracellular degradative system are key players in neurodegenerative
processes. In this study, redox proteomics approach was used to analyze the frontal cortex from DS subjects
under the age of 40 compared with age-matched controls, and proteins found to be increasingly carbonylated
were identiﬁed. Interestingly, our results showed that oxidative damage targets speciﬁcally different compo-
nents of the intracellular quality control system such as GRP78, UCH-L1, V0-ATPase, cathepsin D and GFAP
that couples with decreased activity of the proteasome and autophagosome formation observed. We also
reported a slight but consistent increase of Aβ 1–42 SDS- and PBS-soluble form and tau phosphorylation in
DS versus CTR. We suggest that disturbance in the proteostasis network could contribute to the accumulation
of protein aggregates, such as amyloid deposits and NFTs, which occur very early in DS. It is likely that a
sub-optimal functioning of degradative systems occur in DS neurons, which in turn provide the basis for
further accumulation of toxic protein aggregates. The results of this study suggest that oxidation of protein
members of the proteostatis network is an early event in DS and might contribute to neurodegenerative
phenomena.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Down syndrome (DS) is themost frequent chromosomal abnormal-
ity that causes intellectual disability, resulting primarily from trisomy of
the distal part of chromosome 21 [1]. The neuropathology of DS is com-
plex and includes development of Alzheimer disease (AD) neuropathol-
ogy by 40 years of age, altered free radical metabolism and impaired
mitochondrial function that lead to neuronal degeneration [2–6].
Although by the fourth decade of life, individuals with DS display
many of the neuropathological features of AD, including senile plaques
(SPs) and neuroﬁbrillary tangles (NFTs), individuals may not developl Sciences, Sapienza University
rluigi).
rights reserved.dementia but not until after 50 years of age [7–9]. The accumulation
of amyloid beta (Aβ)-peptide in DS brain can be observed as early as
8–12 years of age, and increases during the lifespan [10,11]. Deposits
of Aβ in DS are ﬁrst seen in the frontal and entorhinal cortex and spread
to other cortical regions and layers with increasing age [6].
However, the onset of dementia typically appears in DS adults
over the age of 50 years suggesting a quite long prodromal phase
where clinical signs are virtually undetectable [12–15]. For these rea-
sons, it has been suggested that DS may serve as a model for the study
of pathophysiological events early in the development of AD neuro-
pathology. The precise mechanisms, by which trisomy 21 lead to the
early-onset of AD-like neuropathology and cognitive decline remains
to be elucidated.
An increasing number of studies have recently shown that oxida-
tive stress (OS) occurs in AD pathogenesis in DS and progression due
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trisomy21 [16]. Increased production of ROS is also accompanied by
mitochondrial dysfunction, both of which are considered to be a trig-
ger for development of AD in DS population [17]. Markers of oxidative
damage have been observed in brain tissues from DS [6,18], and as
early as in fetal DS brain glycation products were measured [19]. A
recent study from our group reported increased levels of oxidative
stress (increased protein oxidation, lipid peroxidation, reduction of
glutathione and thioredoxin levels) and induction of the heat shock
protein (HSP) response in the amniotic ﬂuid from women carrying
DS fetuses compared with non-DS controls [20]. In the same study, we
identiﬁed, by a redox proteomics approach, selective proteins that
showed increased oxidation in amniotic ﬂuid from mothers carrying
DS fetuses comparedwith non-DS controls. These proteins are involved
in iron homeostasis (ceruloplasmin and transferin), lipid metabolism
(zinc-α2-glycoprotein, retinol-binding protein 4 and apolipoprotein
A1) and inﬂammation (complement C9, α-1B-glycoprotein, collagen
α-1 V chain) and possibly play a role in the clinical outcome of DS [20].
Taken together, our ﬁndings and those from others suggest that
oxidative damage is an early event in DS pathology and might con-
tribute to the development of deleterious DS phenotypes, including
abnormal development and AD-like neuropathology.
In addition to OS, characteristic features of neurodegenerative
processes also include accumulation of dysfunctional/damaged protein
aggregates and dysfunction of intracellular degradative systems, such
as autophagy and the ubiquitin-proteasome system (UPS). Growing
evidence highlights the role of autophagy in several age-dependent
neurodegenerative disorders characterized by protein accumulation,
including AD. Indeed, the well-documented decrease in autophagy
function with age may contribute to the accumulation of damaged/
dysfunctional proteins in the brain [21]. Autophagy is one of the
major intracellular proteolytic systems in which components of the
cell are degraded in lysosomes/vacuoles and recycled [22] and may be
regarded a predominantly protective process. Under physiological con-
ditions, and also as a consequence of increased oxidative stress, aber-
rant proteins are targeted for degradation by the UPS [23]. The UPS is
a complex enzymatic pathway that ligates ubiquitin (UBB) to other cel-
lular proteins and assigns them to degradation. The accumulation of Aβ
and hyperphosphorylated tau, as SPs and NFTs respectively, in DS brain,
as well as in AD, suggests that alterations in protein quality control
mechanisms – UPS and autophagy – may be directly or indirectly in-
volved in neurodegenerative processes [24].
In this study, we present the hypothesis that DS brains, prior
to signiﬁcant AD pathology, may show early disturbance of the
proteostasis network possibly linked to increased oxidative stressTable 1
Patients demographic data; AA = African American, Ca = Caucasian, In = Indian.
Subjects PMI Age Sex
Control Y 1 5.8 39 Female
Control Y 2 12 22.8 Male
Control Y 3 14 19.8 Male
Control Y 4 8 33.1 Male
Control Y 5 10 24.4 Male
Control Y 6 10 10.8 Female
Control Y 7 17 39 Female
Control Y 8 20 9 Female
CTR Y 12.1 ± 4.7 24.7 ± 11.6 4F, 4M
DS 1 13 44.5 Female
DS 2 14 19.9 Male
DS 3 12 2.0 Male
DS 4 14 15.5 Male
DS 5 10 40.6 Male
DS 6 12 39.2 Female
DS 7 15 23 Male
DS 8 17 2 Male
DS 13.3 ± 2.1 23.1 ± 16.8 2F, 6Mconditions. Redox proteomics approaches [25] were used to analyze
the frontal cortex from DS brain compared with age-matched controls
to identify proteins with increased carbonylation.
2. Materials and methods
2.1. Subjects
DS and young control cases (8 for each group) were obtained from
the University of California-Irvine Alzheimer's Disease Research
Center Brain Tissue Repository (supported by NIH NIA Grant #P50
AG16573.), the Eunice Kennedy Shriver NICHD Brain and Tissue
Bank for Developmental Disorders (University of Maryland, Baltimore,
MD, contract HHSN275200900011C, Ref. No. N01-HD-9-0011). Table 1
shows the characteristics and demographic data of the subjects included
in the study. The mean post mortem interval (PMI) is 12.1 ± 4.7 h for
CTR subjects and 13.3 ± 2.1 h for DS subjects.
2.2. Sample preparation
Frozen brain tissues samples (frontal cortex) from control and DS
subjects were sonicated in Media 1 lysis buffer (pH 7.4) containing
320 mM Sucrose, 1% of 990 mM Tris–HCl (pH = 8.8), 0.098 mMMgCl2,
0.076 mM EDTA, the proteinase inhibitors leupeptin (0.5 mg/mL),
pepstatin (0.7 μg/mL), aprotinin (0.5 mg/mL), and PMSF (40 μg/mL)
and phosphatase inhibitor cocktail (Sigma-Aldrich, St Louis, MO, USA).
Homogenates were centrifuged at 14,000 ×g for 10 min to remove
debris. Protein concentration in the supernatant was determined by the
Bradford assay (Pierce, Rockford, IL, USA).
2.3. 2D electrophoresis
Brain sample proteins (200 μg) were precipitated in 15% ﬁnal con-
centration of trichloroacetic acid for 10 min in ice. Each individual
sample (8 per group) was then spun down at 10 000 g for 5 min
and precipitates were washed in ice-cold ethanol-ethyl acetate 1:1
solution four times. The ﬁnal pellet was dissolved in 200 μl rehydration
buffer (8 M urea, 20 mM dithiothreitol (DTT), 2.0% (w/v) Chaps, 0.2%
Bio-Lyte, 2 M thiourea, and bromophenol blue). Isoelectric focusing
was performed with ReadyStrip IPG Strips (11 cm, pH 3–10; Bio-Rad,
Hercules, CA, USA) at 300 V for 2 h linearly, 500 V for 2 h linearly,
1000 V for 2 h linearly, 8000 V for 8 h linearly, and 8000 V for 10 h rap-
idly. All the above processes were carried out at room temperature.
After the ﬁrst-dimension run the strips were equilibrated two times,
ﬁrst for 10 min in 50 mM Tris–HCl (pH 6.8) containing 6 M urea,Race Cause of death
Unknown Unknown









Indian Cardiopulmonary arrest: congenital heart disease
Caucasian Unknown
Caucasian Chromosome disorder, trisomy 21
African American HCVD (hypertensive cardiovascular disease)
Caucasian Cancer
African American Pneumonia
African American Cardiac arrhythmia
3AA, 4Ca, 1In ////////
1251F. Di Domenico et al. / Biochimica et Biophysica Acta 1832 (2013) 1249–12591% (w/v) sodium dodecyl sulfate (SDS), 30% (v/v) glycerol, and 0.5%
DTT and again for another 10 min in the same buffer containing 4.5%
iodoacetamide in place of DTT. The second dimension was performed
using 12% precast Criterion gels (Bio-Rad). The gels were incubated in
ﬁxing solution (7% acetic acid, 10% methanol) for 20 min and then
stained for 1 h in Bio-Safe Coomassie gel stain (Bio-Rad, Hercules, CA,
USA) and destained overnight in deionized water. The Coomassie gels
were scanned using a GS 800 densitometer (Bio-Rad, Hercules, CA,
USA).
2.4. 2D oxyblot
For 2D OxyBlot, 2D gels (200 μg of proteins) were blotted onto
nitrocellulose membranes (Bio-Rad, Hercules, CA, USA) and 2,4-
dinitrophenylhydrazine (DNPH) derivatization was performed. Brieﬂy,
membranes were equilibrated in 20% methanol (5 min), then incu-
bated in 2N HCl (5 min), and ﬁnally derivatized in 0.5 mMDNPH solu-
tion (5 min). After derivatization, three washes using 2 N HCl solution
and ﬁve washes using methanol 50% were performed (5 min each).
Finally the membranes were blocked with 3% albumin in T-TBS and in-
cubated with the primary Rabbit anti-DNP antibody (1:100; Millipore,
Billerica, MA, USA) and the secondary antibody alkaline phosphatase-
conjugated anti-rabbit IgG (1:5000; Sigma-Aldrich, St Louis, MO, USA).
The colorimetric reaction was obtained using 5-bromo-4-chloro-3-
indolyl phosphate/nitroblue tetrazolium solution.
2.5. Image analysis
2D gels and 2D blots were analyzed by PDQuest 2D Analysis (7.2.0
version; Bio-Rad, Hercules, CA, USA). PD-Quest spot-detection software
allows the comparison of 2D gels as well as 2D blots from different
groups. Powerful auto-matching algorithms quickly and accurately
match gels or blots and sophisticated statistical analysis tools identify
experimentally signiﬁcant spots. The intensity value for each spot
from an individual gel is normalized using the average mode of back-
ground subtraction. This intensity is afterward compared between
groups using statistical analysis. Statistical signiﬁcance was assessed
using a two-tailed Student t-test. p values b 0.05 were considered sig-
niﬁcant for comparison between control and experimental data (CTR
vs. DS). PD-Quest software allows normalization of a carbonylated
spot intensity on the blot for expression level of the same spot on the
gel. One-dimensional blots were analyzed with Quantity One software
(4.6.9 version; Bio-Rad, Hercules, CA, USA).
2.6. Trypsin digestion and protein identiﬁcation by mass spectrometry
Protein spots identiﬁed statistically different from controls after
PD-Quest analysis were digested in-gel by trypsin. Brieﬂy, spots of
interest were excised and then washed with 0.1 M ammonium bicar-
bonate (NH4HCO3) at room temperature for 15 min. Acetonitrile was
added and incubated at room temperature for 15 min. This solvent
mixture was then removed and gel pieces were dried. The protein
spots were then incubated with 20 ml of 20 mM DTT in 0.1 M
NH4HCO3 at 56 °C for 45 min. The DTT solution was removed and
replaced with 20 ml of 55 mM iodoacetamide in 0.1 M NH4HCO3.
The solution was then incubated at room temperature for 30 min.
The iodoacetamide was removed and replaced with 0.2 ml of
50 mM NH4HCO3 at room temperature for 15 min. Acetonitrile
(200 ml) was added. After 15 min incubation, the solvent was re-
moved, and the gel spots were dried for 30 min. The gel pieces
were rehydrated with 20 ng/ml modiﬁed trypsin (Promega, Madison,
WI, USA) in 50 mM 67 NH4HCO3 with the minimal volume necessary
to cover the gel pieces. The gel pieces were incubated overnight at
37 °C in a shaking incubator. Protein spots of interest were excised
and subjected to in-gel trypsin digestion, and the resulting tryptic
peptides were analyzed with MALDI ToF and automated nanosprayNanomate Orbitrap XL MS/MS platform [26]. MALDI-ToF MS analyses
were performed in a Voyager-DE STR instrument (Applied Biosystems,
Framingham, MA, USA) equipped with a 337 nm nitrogen laser and
operating in reﬂector mode. Mass data were obtained by accumulating
several spectra from laser shots with an accelerating voltage of 20 kV.
Two tryptic autolytic peptides were used for the internal calibration
(m/z 842.5100 and 2807.3145). Data were analysed by MoverZ pro-
gram (v. 2002, http://bioinformatics.genomicsolutions.com), according
to default parameters. Identiﬁcation by peptidemass ﬁngerprint (PMF),
with the mono-isotopic mass list, after exclusion of expected contami-
nant mass values by Peak Erazor program (http://www.protein.sdu.
dk/gpmaw/Help/ PeakErazor/peakerazor.html), was performed using
the Mascot search engine (v. 2.3) against human SwissProt database
[(Swis-sProt 2011_08 (531473 sequences; 188463640 residues)]. Up
to one missed cleavage, 50 ppm measurement tolerance, oxidation
at methionine (variable modiﬁcation) and carbamidomethylation at
cysteine (ﬁxed modiﬁcation) were considered. Identiﬁcations were
validated when the probability-based Mowse protein score was signif-
icant according to Mascot. The Orbitrap MS was operated in a data-
dependentmodewhereby the eightmost intense parent ionsmeasured
in the FT at 60,000 resolution were selected for ion trap fragmentation
with the following conditions: injection time 50 ms, 35% collision
energy. MS/MS spectra were measured in the FT at 7500 resolution,
and dynamic exclusion was set for 120 s. Each sample was acquired
for a total of 2.5 min. MS/MS spectra were searched against the IPI
Worms Database using SEQUEST with the following criteria: Xcorr >
2.0, 2.5, 3.0 for +2, +3,and +4 charge states, respectively, and
p value (protein and peptide) b 0.01. IPI accession numbers were
cross-correlated with SwissProt accession numbers for ﬁnal protein
identiﬁcation.2.6.1. Aβ levels
Frozen cortical samples were extracted sequentially in ice cold
phosphate buffered saline (PBS, pH 7.4) with a complete protease
inhibitor cocktail (PIC) (Amresco, Solon, OH), and centrifuged at
20,800 ×g for 30 mins at 4 °C. Following centrifugation, the superna-
tant was collected and the pellets were sonicated (10 × 0.5 sec pulses
at 100W, Fisher Sonic Dismembrator) in 2% SDS with PIC followed by
centrifugation (as above, at 14 °C). The supernatant was again col-
lected, and the remaining pellets were sonicated in 70% formic acid
(FA) followed by centrifugation at 20,800 ×g for 1 h at 4 °C. Aβ was
measured in tissue samples using a standard, well-characterized,
two-site sandwich ELISA as described previously [6]. Brieﬂy, an
Immulon 4HBX plate was coated with 0.5 ug/well of antibody, incu-
bated overnight at 4 C, then blocked with a solution of Synblock
(Serotec), as per the manufacturer's instructions. Antigen capture was
performed using monoclonal antibody Ab9 (against Human Aβ1–16).
Antigen detection was performed using biotinylated antibodies 13.1.1.
(end speciﬁc for Aβ40), and 12F4 (end speciﬁc for Aβ42; Covance,
Princeton, NJ).
Formic acid extracted material was initially neutralized by a 1:20
dilution in TP buffer (1 M Tris base, 0.5 M Na2HPO4), followed by a
further dilution as needed (1:100 to 1:400) in Antigen Capture buffer
(AC) (20 mM Na3PO4, 0.4% Block Ace (AbD Serotec, Raleigh, NC),
0.05% NaN3, 2 mM EDTA, 0.4 M NaCl, 0.2% BSA, 0.05% CHAPS, pH 7).
SDS soluble fractions were diluted (1:20) in AC buffer alone. PBS
fractions were diluted 1:4 in AC buffer alone. A peptide standard
curve of Aβ was run on the same plate for comparison, and standards
and samples were run at least in duplicate; Aβ values were deter-
mined by interpolation relative to the standard curve. Plates were
washed between steps with standard PBS containing 0.05% Tween-20
(2–4×) followed by PBS (2–4×). Plates were developed with
TMB reagent (Kirkegaard & Perry Laboratories), stopped with 6%
o-phosphoric acid, and read at 450 nm using a BioTek multiwell plate
reader.
Fig. 1. Bar graph and WB image of tau phosphorylation (Ser404) and expression levels
in CTR and DS samples.
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For Western blot, 30 μg of proteins (CTR and DS) were separated
by 12% SDS– PAGE and blotted onto a nitrocellulose membrane
(Bio-Rad, Hercules, CA, USA). Membranes were blocked with 3%
bovine serum albumin in T-TBS and incubated for 1 h and 30 min at
room temperature with primary anti-LC3 antibody (1:100; Novus
Biologicals, Littleton, CO, USA), anti proteasome 20S core subunit
(1:1000; ENZO Life Science, Farmingdale, NY, USA) and 19S 10B
(1:500; Novus Biologicals, Littleton, CO, USA), anti-pTau (ser404)
and anti-Tau (1:500; Santa Cruz Biotechnology, Dallas, TX, USA) and
for 1 h at room temperature with secondary antibody horseradish
peroxidase-conjugated anti-rabbit IgG (1:5000; Sigma–Aldrich, St
Louis, MO, USA). Membranes were developed with the Super Signal




Chymotrypsin-like, trypsin-like and caspase-like activity was
assayed in young CTR and DS samples according to Keller et al. [27].
Brieﬂy brain tissues were homogenized in proteolysis activity buffer
(Tris–HCl 10 mM, pH 7.4, DTT 0.5 mM, ATP 5 mM, 0.035%SDS and
MgCl2 5 mM) at 4 °C. Protein determination was performed with
Coomassie Protein Assay (Pierce, Rockford, IL, USA). Protein (250 μg)
were incubated 30 min at 37 °C with the ﬂuorogenic chymotrypsin-
like substrate, succinyl-LLVY-4-methylcoumaryl-7-amide, with the
trypsin-like substrate Z-ARR-4-methylcoumaryl-7-amide and with the
caspase-like substrate Z-LLE-4-methylcoumaryl-7-amide (Sigma-Aldrich,
St Louis, MO, USA), to a ﬁnal concentration of 50 μM. The reaction was
blocked in ice and ﬂuorescence measures were obtained at 380/460 nm
excitation and emission, respectively. The background ﬂuorescence
was obtained by incubating homogenized samples with MG132
(Sigma-Aldrich, St Louis, MO, USA) a potent, reversible and cell-
permeable proteasome inhibitor, to a ﬁnal concentration of 60 μM.
The incubation with MG 132 was performed 30 min before addition
of the proteasome substrate.
2.8.2. Cathepsin D
CatD activity was measured according to Grimm et al. [28] by
measuring the changes in ﬂuorescence of DS and CTR brain samples
incubated with the ﬂuorogenic substrate, Mca-Gly-Pro-Ile-Leu-Phe-
Phe-Arg-Leu-Lys (Dnp) -D-Arg-NH2 (ENZO Life Science, Farmingdale,
NY, USA). Brain tissues, 8 CTR and 8 DS, were homogenized on ice, in
100 mM sodium acetate buffer pH 3.5, 4 mM EDTA and 0.2% Triton
X100. Homogenated tissues were incubated with substrate 20 μM in
50 mM sodium acetate buffer pH 4.0 at 40 °C for 1 h. The reaction
was blocked by adding TCA 5% and ﬂuorescence was measured at
328/393 Ex/Em respectively.
2.8.3. UCH-L1
The activity of UCH-L1 was measured by determining the rate
of conversion of ubiquitin-C-terminal 7-amido-4-methylcoumarin
(Ub-AMC) (ENZO Life Science, Farmingdale, NY, USA) to ubiquitin
and free AMC [29]. In the assay, buffer (50 mM Hepes, pH 7.0,
10 mM DTT, and 0.1 mg/ml ovalbumin) was mixed with 200 μg of
frontal cortex homogenate of 8 samples per group for 1 h. Then 10 μl
of 200 nM Ub-AMC was added to the enzyme solution, and cleavage
of AMC from Ub-AMC was monitored at 380/460 nm excitation and
emission respectively.
2.9. Statistical analysis
All statistical analyses were performed using Student's t-test.
Signiﬁcance was accepted if the p value b 0.05.3. Results
3.1. Carbonylation results in DS vs. CTR frontal cortex
The redox proteomics analyses showed increased speciﬁc carbonyl-
ation levels (normalized to expression levels) of six proteins in frontal
cortex of DS subjects compared with non-DS cases (Fig. 2 and
Table 3). These proteins identiﬁed by MS/MS analysis were: ubiquitin
carboxyl-terminal hydrolase 1 (UCH-L1) with 2.12-fold increase,
cathepsin D (CatD) with 2.11-fold increase, 78 kDa glucose-regulated
protein (GRP78) with 12.9-fold increase, V0-type proton ATPase
subunit B, brain isoform (V0-ATPase) with 3.9-fold increase, glial
ﬁbrillary acidic protein (GFAP) with 8-fold increase and succinyl-
CoA:3-ketoacid-coenzyme A transferase 1 mitochondrial (SCOT-1)
with 7.9-fold increase (Fig. 3 and Table 3). The expression levels of the
above oxidativelymodiﬁed proteins revealed a slight increase, between
1.15- to 1.27-fold, for UCH-L1, CatD, GRP78 and GFAP, while no alter-
ations for V0-ATPase and a decrease of about 2-fold (0.48) for SCOT-1
were found (Fig. 3 and Table 3).3.2. Aβ levels and tau phosphorylation
We analyzed Aβ 1–40/42 PBS-soluble, SDS-soluble and FA
extracted levels in DS compared to CTR subjects. No signiﬁcant in-
crease in Aβ 1–40 forms but signiﬁcant slight increases for Aβ 1–42
PBS-soluble, SDS-soluble and FA extracted levels were found in DS
compared to CTR. Increased phosphorylation (ser404) in DS frontal
cortex compared to CTR was observed, consistent with the notion
that trisomy of Chr 21 leads to tau hyperphosphorylation (Fig. 1).3.3. Proteasome subunits levels and activity
In order to investigate the functionality of UPS we analyzed
proteasome levels (20S and 19S) by WB analysis and proteasome
activity by speciﬁc assay. The expression levels data show a higher
expression of 20S subunit than the 19S subunit of about 80% in CTR
subjects, while in DS subject the expression difference of the two
subunits is only about 10% (Fig. 4, panel A). The chymotrypsin-like
proteasome activity assay demonstrated a signiﬁcant decrease of
proteasome functionality (about 20%) in DS subjects compared with
CTR as well as trypsin-like and caspase-like activities that demon-
strates about 35 and 40% decrease respectively (Fig. 4, panel B).
Fig. 2. Representative 2D gel and blot from DS and CTR samples. The spots showing signiﬁcantly increased carbonyl levels are labeled. The spot numbers indicated on the maps are
the same as those listed in Table 2.
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To analyze if the increased carbonylation of CatD may affect protein
function, wemeasured CatD enzyme activity in the two groups of brain
samples. A signiﬁcant (p b 0.05) slight increase of CatD activity in DS
samples, of about 10% compared to CTR samples, was demonstrated
(Fig. 5A). As well, the activity of UCH-L1 was measured in order to
determine any alteration on its functionality.
Interestingly, UCH-L1 enzyme activity present a decrease of about
30% in DS compared to CTR.
3.5. LC3 II/I levels
Since our redox proteomics results suggest the impairment of the
autophagic pathway, we analyzed by Western blot the expression
levels of LC3 II/I, a broadly recognized marker of autophagy activity.
Our results shown in Fig. 6 demonstrate about a 40% decrease (from
100 to 60%) of LC3 II/I levels in DS compared to CTR frontal cortex
samples.
4. Discussion
Growing evidence supports the occurrence of chronic oxidative
injury in the brain that could imply a risk factor for subsequent
neurodegeneration in aged DS patients [6,30]. The present study
aimed to shed light on molecular pathways, perturbed by oxidative
stress, which may play a key role in the neurodegenerative phenom-
ena occurring in DS. By applying redox proteomics approaches to
analyze the extent of oxidative damage in the cortex of DS brainTable 2







CTR (Avg) 52.9 233.6 1502.7
DS (Avg) 147.4⁎ 4315.3⁎ 3100.9⁎
⁎ Signiﬁcant differences.compared with age-matched controls, we were able to identify spe-
ciﬁc oxidatively modiﬁed proteins. Our ﬁndings are discussed in
light of the well-established effect of oxidative damage on protein
functionality, which results in altered, reduced or toxic gain of func-
tion [25].
Interestingly, the majority of these proteins are members of the
intracellular Quality Control (QC) system including GRP78, UCH-L1,
Cat D, V0-ATPase and GFAP. Our ﬁndings suggest that chronic expo-
sure to OS may participate to impair the proteostasis network,
which in addition to maintaining correct protein homeostasis is also
fundamental to counteract accumulation of Aβ and NFTs [31].
We observed a slight increase of Aβ 1–42 PBS-soluble, SDS-soluble
and FA extracted levels in DS frontal cortex compared to CTR and also
increased levels of tau phosphorylation. Our results are, consistent
with reported increased Aβ levels early in DS, prior to extracellular
Aβ deposits [32]. Subsequently high molecular weight aggregates of
Aβmay accumulate, enhancing the deposition of plaques and, through
Aβ oligomers, ROS production [14,33]. In addition aberrantly phosphor-
ylated tau conceivably might accumulate as a consequence of impaired
activity of bothproteasome and autophagy systems thus contributing to
neurodegeneration in DS.
Intracellular Aβ oligomers may accumulate in the endoplasmic
reticulum (ER) and activate the unfolded protein response (UPR)
[34,35]. UPR is a primary line of defense of the cell against toxic accu-
mulation of misfolded proteins [24,36] and UPR occurs mainly in
three steps: 1) up-regulation ofmolecular chaperones to assist in protein
refolding; 2) arrest of further protein synthesis; and 3) ubiquitination of
misfolded proteins and their translocation to proteasomes for degrada-
























1 Ubiquitin carboxyl-terminal hydrolase 1 (UCLH-1) P09936 40 25151/5.33 b0.05 1.19 2.52 * 2.12 ↑
2 Cathepsin D (CatD) P07339 16 45037/6.10 b0.05 1.15 2.42 * 2.11 ↑
3 78 kDa glucose-regulated protein (GRP78) P11021 40 72402/5.07 b0.05 1.27 * 16.38 * 12.9 ↑
4 V0-type proton ATPase subunit B, brain isoform (V0-ATPase) P21281 30 56807/5.57 b0.05 0.99 3.86 * 3.9 ↑
5 Glial ﬁbrillary acidic protein (GFAP) Q96KS4 28 49907/5.42 b0.05 1.19 9.52 * 8.0 ↑
6 Succinyl-CoA:3-ketoacid-coenzyme A transferase 1,
mitochondrial (SCOT-1)
P55809 23 56578/7.14 b0.05 0.48 * 3.87 * 7.9 ↑
1254 F. Di Domenico et al. / Biochimica et Biophysica Acta 1832 (2013) 1249–1259As the ﬁrst step, the protective mechanism used by cells to adapt
to stress of the ER is the induction of members of the glucose-
regulated protein (Grp) family, mainly GRP78. The induction of mam-
malian Grp proteins in response to ER stress involves a complex
network of regulators and novel mechanisms. Our data demonstrate
a relationship between OS and protein misfolding in DS brain, show-
ing that GRP78 can be a target of OS in vivo. Oxidative damage may
result in GRP78 dysfunction (inability to bind to the misfolded pro-
teins), which provides a conceivable mechanistic link between deﬁ-
cits in molecular chaperones, accumulation of misfolded proteins,
and risk of cognitive decline. According to our previous studies
[20,37], increased levels of GRP78 indicate the induction of the UPS
system, as results of the presence of unfolded/misfolded proteins;
however, the pro-oxidant environment in DS appears to result in
GRP78 oxidation that might lead to dysfunction of the UPR system.
Upon activation of ER-stress response, ERADmediates ubiquitination
of misfolded proteins, which occur in the cytoplasm [38]. Here,
the proteasome system involves the activity of different enzymes,
ubiquitinating and deubiquitinating enzymes, leading to degradationsFig. 3. Bar graph of identiﬁed proteins expression, carbonylationof cytsolic proteins as well as proteins that fail to pass the QC in the ER.
Protein ubiquitination/deubiquitination has emerged as an important
mechanism for regulating a variety of cellular processes, including pro-
tein degradation, synaptic function, and neuronal apoptosis [39]. We
observed that UCH-L1 is a target of oxidative damage in DS brains, and
its oxidative modiﬁcation likely leads to a decreased function in DS
brain as demonstrated by activity assay. UCH-L1 has an important role
in recycling of ubiquitin through hydrolysis of peptide-ubiquitin bonds
and processing of ubiquitin precursors, but it also possesses ubiquitin
ligase activity UCH-L1 possesses a well-characterized de-ubiquitinating
activity that catalyzes the hydrolysis of carboxyl-terminal esters and
amides of ubiquitin to generate monomeric ubiquitin [40]. Oxidative
modiﬁcations causing irreversible alteration in the conformation and/
or enzymatic activity of UCH-L1 result in deleterious effects on neuronal
function and survival. Aberrant ubiquitin hydrolase and/or ligase activity
for the identiﬁed oxidative modiﬁcations of UCH-L1 might lead to dys-
function of the neuronal ubiquitination/de-ubiquitination machinery,
causing synaptic deterioration and neuronal degeneration in DS as
well as demonstrated in AD brains [41–45]. Previous studies from ourand carbonylation/expression values in CTR and DS samples.
Fig. 4. Panel A: Bar graph of proteasome subunits (20S and 19S) levels in CTR and DS samples measured by WB analysis. Panel B: Proteasome functionality measured by enzymatic
assay of chymotrypsin-like, trypsin-like and caspase-like activity in CTR and DS samples. *p b 0.01.
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decreased in AD brain and also that this enzyme is oxidatively modiﬁed
[44]. One of the major consequences of aberrant UCH-L1 activity is an
impaired proteasome proteolytic system, which will lead to accumula-
tion of damaged proteins and formation of protein aggregates. The pro-
teolytic core of the proteasome or “20S proteasome” is involved in the
degradation of oxidatively modiﬁed proteins [46–48]. Oxidatively modi-
ﬁed proteins can undergo chemical fragmentation or form aggregates
because of covalent cross-linking reactions and increased surface hydro-
phobicity [49]. The recognition of hydrophobic amino acid residues
of oxidized proteins and their subsequent degradation by the 20S
proteasome could be a selectivemechanism to remove oxidatively dam-
aged proteins from the cell [50]. Although we found increased levels of
the 20S subunit, the activities of trypsin-like, chymotrypsin-like and
caspase-like of the proteasome were decreased in DS brain compared
with age-matched controls. It is likely that proteasome activation may
be a signal to enhance protein degradation in affected neurons to preventFig. 5. Panel A: Cathepsin D activity in CTR ad DS samples measured by ﬂuorescent assay a
ﬂuorescent assay at 380/460 Ex/Em n = 8; *p b 0.05.the formation of toxic aggregates, but at the same time the enzyme is
directly or indirectly damaged by ROS and its functionality is affected.
Another major degradation system reported to be activated by ER
stress in vitro is autophagy [51–53]. During autophagy, a double
membrane is wrapped around an organelle or protein aggregate and
this autophagosome subsequently fuses with a lysosome, forming an
autophagolysosome where degradation takes place. Healthy neurons
only rarely show autophagic structures, whereas many autophagic
vacuoles can be observed in AD neuronal cell bodies and dystrophic
neuritis [54].
Autophagy is considered as a basal cellular mechanism to control
homeostasis of intracellular proteins and organelles. However, autoph-
agy can be also induced to protect cells under various physiological
stresses such as nutrient depletion, genotoxic agents, aggregated pro-
teins, or cytokines. In particular, if the ﬁrst defense mechanism by
non-enzymatic molecules and enzymatic scavengers is overwhelmed
under oxidative stress, autophagy plays a crucial role in cell protectiont 328/393 Ex/Em. Panel B: UCH-L1 activity assay in CTR and DS samples measured by
Fig. 6. LC3 II/I expression levels in CTR and DS samples. Panel A: Bar graph of the ratio
of LC3 II and I values compared to β actin loading control. Panel B: Representative
bands of LC3 I and II immunodetection in WB analysis. n = 8; *p b 0.05.
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Unfortunately, these defense mechanisms are not always enough to
overcome the oxidative stress, resulting in autophagic cell death (type
II programmed cell death) that is distinct from apoptosis (type I
programmed cell death) [56]. However, the mechanistic basis coordi-
nating autophagic processes under oxidative stress is still not clear
and further studies are needed.
We hypothesize that the oxidation of V0-ATPase pump could lead
to autophagy dysfunction. This proton pump is essential for acidic
lysosomal pH. Mutation of lysosomal ATPase genes is a well-recognized
risk factor for autophagy related neurodegenerative diseases [57,58]. It
is reasonable to speculate that once oxidized V0-ATPase has altered abil-
ity to regulate intracellular pH thus affecting proper lysosome function-
ality and autophagy, as was previously seen in a PD model [59]. In
addition, a recent report showed that V0-ATPase is necessary for amino
acids to activate mTORC1, thus suggesting that V0-ATPase is an active
component of the mTOR pathway [60]. Recently, it has been demon-
strated that PS1 directly regulates the acidiﬁcation of lysosomes by con-
trolling the targeting of V0­ATPase to these vesicles. AD­linked PS1
mutations or neurons lacking PS1 result in defective lysosomal proteol-
ysis, having a detrimental impact on protein homeostasis and neuronal
function. Restoration of lysosomal function by genetic intervention was
able to prevent neuropathology and cognitive deﬁcits of an AD mouse
model [61,62].
A characteristic hallmark of autophagic activation is the formation
of cellular autophagosome punctae containing LC3 II. A decreased
ratio of LC3II/I is an index of decreased autophagosome formation,
as we show in our results, which suggest a decrease of autophagic
ﬂux occurring early in DS brain. Recent studies reported that insulin-
like growth factor binding protein-3 (IGFBP-3) enhances autophagy
via binding to GRP78 [63], consistentwith previous studies that showed
that GRP78 is required for stress-induced autophagy [64]. In this con-
text, the oxidation of GRP78, as previously mentioned, could also con-
tribute to autophagy dysfunction.
A newly recognized member of the autophagy machinery is also
GFAP. GFAP is expressed in activated astrocytes, where it is thought
to help maintain mechanical strength, as well as the shape of cells
[65]. The exact function of GFAP remains an enigma, despite thehuge number of studies using it as a marker for astrocyte activation.
Increased expression of GFAP is a characteristic feature of reactive
astrocytes during chronic inﬂammation that could be associated
with the presence of tangles, neuritic plaques and Aβ pathology,
and is closely associated with the maturation of the astrocyte [66].
The levels of GFAP dynamically respond to aging as well as to neuro-
degenerative lesions, [67,68], and many studies have shown that the
amount of GFAP generally increases in neurodegenerative diseases
such as AD [69]. A recent study showed for the ﬁrst time that
GFAP is an important regulator for chaperone-mediated autophagy
(CMA), a degradative mechanism for cytosolic proteins in lysosomes
[70]. GFAP was proposed to interact at the lysosomal membrane
either with the lysosome-associated membrane protein type 2A
(LAMP-2A), an important component of the translocation complex,
or with the elongation factor 1a (ef1a). Since CMA is activated as
part of the cellular response to oxidative stress required for targeting
oxidized proteins to lysosomes, oxidation of GFAPmight contribute to
disrupt the complex network involved in autophagy processes [71].
Previous in vitro studies showing the carbonylation of GFAP by Aβ
(1–42) are consistent with our hypothesis [72].
Intriguingly, we found that CatD is oxidized in DS compared with
non-DS controls resulting in a slight increase of enzyme activity. CatD
is normally localized within lysosomes and participates in the degrada-
tion of proteins, downstream autophagy, and processing of precursor
proteins [73,74]. Evidence exists that CatD is involved in AD pathogen-
esis [75–77] and CatD has been found within neuritic plaques in
AD brains [78,79]. Indeed, it has been reported that CatD possess
beta-secretase activity and this function may play a key role in Aβ pro-
cessing [80]. The hypothesis of a CatD role in amyloidogenesis initially
came from the ﬁrst evidence by Nixon and co-workers in 1990 [79].
The authors observed in sections from AD brains, stained by antisera
to both cathepsin D and B, high levels of inmunoreactivity in senile
plaques. However, APP intracellular processing to generate Aβ has
remained controversial. It has been proposed that APP cleavage may
occur in different organelles along the endo-lysosomal pathway includ-
ing the ER, the Golgi apparatus, the plasma membrane, early, late, or
recycling endosomes and the lysosome [81]. It is likely that a cross-
talk between these different organelles may occur and the exact loca-
tion of APP processing would depend on the active trafﬁc of the precur-
sor and the secretase enzymes. Within this frame, we suggest that
increased oxidation of CatD results in a “gain of its function” as already
demonstrated for other proteins, such as SOD-1 in the case of
amyotrophic lateral sclerosis [29,82]. The activation of CatD, resulting
either from its increased expression or enzyme activity, may be a com-
pensatory response to partially disturbed autophagy and/or alternatively
be involved in APP processing thus resulting in increased Aβ production,
as occurs early in DS pathology [77,80].
Recent in vitro data suggest that activation of lysosomal cathepsin,
either D and B forms, may be reﬂective of early compensatory pro-
cesses that keep protein accumulation events partially in check and
contribute to the progressive nature of AD pathology [83].
All the above-mentioned processes rely, to varying extents, on ATP
consumption and are closely related tomitochondrial integrity. Indeed,
the AD brain has altered mitochondrial functions and altered glucose
metabolism, which ultimately culminates in decreased ATP synthesis
[84]. Alteration in the brain metabolic proﬁle of AD is associated with
a concomitant metabolism of ketone bodies to compensate for the
decline in glucose-driven ATP generation. It has been demonstrated
that ketone bodies and fatty acids can replace glucose as the primary
energy source for brain under pathophysiological conditions [85]. We
found in the current study that succinyl-CoA:3-ketoacid-coenzyme
A transferase 1 (SCOT) mitochondrial, is more oxidized in DS. This
homodimeric mitochondrial matrix enzyme plays a central role in
extrahepatic ketone body catabolism by catalyzing the reversible trans-
fer of coenzyme A from succinyl-CoA to acetoacetate (SCOT). Thus,
oxidation of SCOT might indicate a partial failure of compensatory
Scheme 1. Putative scenario of QC protein oxidation and Aβ and hpTau degradation/accumulation in DS brain.
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utilization.
5. Conclusions
Our study suggests that DS may be included in the family of
“protein deposition disorders”, where inappropriate protein deposits
arise when the normally efﬁcient protein folding quality control sys-
tem is overwhelmed [86]. The correct balance between folding and
degradation of misfolded proteins is critical for cell viability [87].
Taken together, our ﬁndings highlight that oxidative damage targets
mainly proteasome and autophagy systems in DS subjects and con-
tribute to disturbance of the proteostasis network. The cross-talk be-
tween different members of the QC machinery is essential to avoid
dangerous accumulation of misfolded/aggregated proteins [21].
We suggest that accumulation of Aβ and NFT in DS may result
both from its increased production and from the disruption of cellular
degradative systems (e.g. UPS and autophagy). Indeed studies from
Nixon's group demonstrated alterations in function of the endosomal-
autophagic-lysosomal system in DS [88]. In this scenario chronic oxida-
tive stress occurs in DS brain and contributes to Aβ and NFT accumula-
tion, fostering the question: how do neuronal cells try to survive?
ER stress elicits the unfolded protein response, including up-
regulation of molecular chaperones and induction of ERAD. In ERAD,
the Aβ oligomers are translocated from the ER into the cytoplasm to
be degraded by proteasomes. Damaged ER and undergraded Aβ olig-
omers in the cytoplasm are engulfed by autophagosomes and sorted
to lysosomes to be digested. Oxidation of GRP78, UCH-L1, CatD, V0-
ATPase and GFAP demonstrate modiﬁcation and relative dysfunction
of proteins involved at different steps of the proteostasis network.
This dysfunction is exacerbated by the decreased activities of the
proteasome and the potential impairment of autophagy.
In parallel, hyperphosphorylated tau might be able to escape dys-
functional quality control mechanisms represented by ER, proteasomeand autophagy activities, leading to its aggregation and NFT formation
(Scheme 1).
Though observational and comparative, it is tempting to speculate
that DS neurons are characterized by increased oxidative stress com-
bined with defective degradative systems which in turn results in
further accumulation of toxic protein aggregates. Since DS may be con-
sidered a prodromal human model of AD, our study suggests that the
impairment of proteostatis network represents an early event in neuro-
degenerative phenomena. Future studies directed to investigatewhether
activation/modulation of the QC system may be a therapeutic target are
underway.
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